Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and actionable clinical information, now offers a new laboratory‐based urine test for the detection of commonly prescribed Z‐Drugs.
Scientists in the open access journal PLOSONE reported today on a comprehensive systematic evaluation of compliance to prescribed treatment medications and abstinence from psychoactive drug abuse in chemical dependence programs.
The U.S. Drug Enforcement Administration (DEA) has reclassified hydrocodone-combination products as the more restrictive Schedule II drugs in an attempt to curb drug abuse. The DEA published the Final Rule in the Federal Register on Aug. 22. The Final Rule will take effect in 45 days and will apply to “all pharmaceuticals containing hydrocodone currently on the market in the United States.”
New guidelines drafted by the American Pain Society (APS) for the safe administration of methadone for the first time focus particular attention on the potential for abuse and misuse of the drug, highlighting the need for additional awareness and education within the pain management community, after a significant increase in deaths related to its use.
Dominion Diagnostics recently hosted a donation drive to benefit Project Sweet Peas, an organization that provides comfort to families with children in the Women and Infants neonatal intensive care unit (NICU). There are a number of Dominion Diagnostics employees who have been beneficiaries of support services from Project Sweet Peas.
Prescription drug abuse is a serious public health problem that has reached crisis levels across the United States. The governors of five New England states met earlier this week to discuss how to combat prescription drug abuse and diversion. The American Medical Association hopes they will focus on a five-pronged comprehensive, public health approach that emphasizes treatment and prevention.
Kenneth Blum, PhD, President and CEO of IGENE, LLC, has long been associated with leading drug monitoring laboratory Dominion Diagnostics in a scientific research and advisory role. Blum, who sits on Dominion’s Addiction and Scientific Advisory Board, was recently appointed Chief Scientific Advisor to Dominion Diagnostics.
Dominion Diagnostics, a leading national provider of drug testing, medication monitoring, and clinical support services, launched new testing today that will detect Kratom use. Dominion’s Kratom assay will expand the company’s designer drug testing menu, which already includes detection of synthetic cannabinoids (Spice/K2) and synthetic cathinones (bath salts).
Dominion Diagnostics is pleased to announce its renewed commitment to support education and advancement in addiction medicine and behavioral healthcare. For its second consecutive year, Dominion is the Series Thought Leadership Partner for the 2014 Addiction Professional Panel Series hosted by Vendome Healthcare Media.